Rodolfo Pedro Rothlin (Rodolfo Rothlin)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 3

Top Topics

Vascular Smooth Muscle Cells

Randomized Controlled Trial

Coronavirus Disease

Top Venues

Drug development research

Journal of the American Heart Association

Pharmacology research & perspectives

This page only lists publications with an associated author ORCID identifier.

Publications

Rodolfo Pedro Rothlin, Facundo Germán Pelorosso, Mariano Duarte, Liliana Nicolosi, Fernandez Criado Ignacio, María Victoria Salgado, Héctor Vetulli
Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19. Pharmacology research & perspectives 11 (2) (2023)
Sonali Rukshana Gnanenthiran, Claudio Borghi, Dylan Burger, Bruno Caramelli, Fadi Charchar, Julio Alonso Chirinos, Jordana B Cohen, Antoine Cremer, Gian Luca Di Tanna, Alexandre Duvignaud, Daniel Freilich, D H Frank Gommans, Abraham Edgar Gracia-Ramos, Thomas A Murray, Facundo Pelorosso, Neil R Poulter, Michael A Puskarich, Konstantinos D Rizas, Rodolfo Pedro Rothlin, Markus P Schlaich, Michael Schreinlecher, Ulrike Muscha Steckelings, Abhinav Sharma, George S Stergiou, Christopher J Tignanelli, Maciej Tomaszewski, Thomas Unger, Roland R J van Kimmenade, Richard D Wainford, Bryan Williams, Anthony Rodgers, Aletta Elisabeth Schutte, null null
Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension. Journal of the American Heart Association 11 (17) (2022)
Rodolfo Pedro Rothlin, Héctor Miguel Vetulli, Mariano Duarte, Facundo Germán Pelorosso
Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19. Drug development research 81 (7) (2020)